^
    Back
    Association details:
    Biomarker:CHD1 deletion
    Cancer:Prostate Cancer
    Drug:abiraterone acetate (CYP17A1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Mol Cancer Res
    Title:

    Circulting Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

    Published date:
    03/26/2021
    Excerpt:
    Men who had progression-free survival of ≤3 months despite enzalutamide/abiraterone treatment were more likely to have baseline CTC genomic loss of CHD1, PTEN, PHLPP1, and ZFHX3 and gains of BRCA2, KDM5D, MYCN, and SPARC.
    DOI:
    10.1158/1541-7786.MCR-20-0975
    Trial ID:
    PROPHECY
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

    Published date:
    08/01/2018
    Excerpt:
    CONTRADICTING EVIDENCE: SPOP mutations and/or CHD1 loss was associated with a higher response rate to abiraterone (SPOP: OR, 14.50 P = 0.001…SPOP-mutated mCRPCs are strongly enriched for CHD1 loss. These tumors appear highly sensitive to abiraterone treatment.
    DOI:
    10.1158/1078-0432.CCR-18-0937